Heidelberg Pharma to Unveil Pivotal Phase I/IIa Data for ATAC Candidates at ASH 2026

Heidelberg Pharma will present new clinical data for its Amanitin-based ADC candidates pamlectabart tismanitin (HDP-101) and HDP-102 at the 68th ASH Annual Meeting, highlighting the potential of its ATAC platform in multiple myeloma and B-cell malignancies.

Chicago Metrowire Staff
••Healthcare
Heidelberg Pharma to Unveil Pivotal Phase I/IIa Data for ATAC Candidates at ASH 2026

Heidelberg Pharma AG will present new clinical data from its Phase I/IIa study of lead candidate pamlectabart tismanitin (HDP-101) in an oral presentation and from its second candidate HDP-102 in a poster session at the 68th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans from December 12 to 15, 2026. The announcement, reported by NEWMEDIAWIRE, signals important clinical validation for the company's Amanitin-based Antibody Drug Conjugate (ATAC) technology.

The oral presentation, scheduled for Saturday, December 12, will detail the first-in-human Phase 1/2a study of pamlectabart tismanitin, an anti-BCMA ADC for relapsed or refractory multiple myeloma (RRMM), a bone marrow cancer with high unmet medical need. The Phase I dose-escalation portion, which included ten patient cohorts and concluded in April 2026, determined the recommended Phase 2 dose (RP2D) for the ongoing Phase IIa expansion. According to the company, pamlectabart tismanitin demonstrated consistent clinical activity with a favorable safety profile in heavily pretreated RRMM patients, supporting its potential as a novel payload BCMA-targeted therapy. The abstract is available in the ASH® ANNUAL PROGRAM.

The poster presentation on Sunday, December 13, will cover HDP-102, a first-in-class CD37-targeted Amanitin-based ADC for relapsed/refractory B-cell malignancies. In the ongoing Phase I study, three patients were treated with 40 µg/kg in the first cohort; treatment was well tolerated, and initial signs of biological activity were observed at that very low dose. Two patients showed stabilization of disease with regression and reduction of lymph nodes. The safety committee recommended increasing the dose to 65 µg/kg for the second cohort. However, Heidelberg Pharma announced in September 2025 a strategic decision to discontinue the study and is now exploring partnership opportunities to support the program's continuation. Abstract details are also accessible via the ASH® ANNUAL PROGRAM.

These presentations matter because they provide the first clinical evidence that Heidelberg Pharma's ATAC platform, which uses Amanitin derived from the green death cap mushroom, can produce meaningful anti-tumor activity with a manageable safety profile in two distinct hematologic cancers. For pamlectabart tismanitin, the selection of an RP2D and preliminary efficacy in RRMM are critical steps toward a potential registrational path, especially given the candidate's Orphan Drug and Fast Track designations from the FDA. The HDP-102 data, while early, offer proof-of-concept for CD37 targeting and may attract partners for further development. Overall, the ASH data could bolster confidence in the company's pipeline, which also includes preclinical candidates HDP-103 and HDP-104, and may open doors to collaborations. More information is available at http://www.heidelberg-pharma.com/.

Blockchain Registration

QR Code for Blockchain Registration